Latest Articles

Publication Date
Therapeutic Potential of Linalool in Endometriosis: Modulation of Oxidative Stress, Inflammation, and Apoptosis in a Rat Model.

Endometriosis (EMS) is a chronic inflammatory disease affecting 10%-15% of women of reproductive age and is a major cause of infertility. This study explores the therapeutic effects of linalool, a …

Published: Sept. 9, 2026, midnight
Self-reported fertility problems and their socio-demographic and health correlates: a cross-sectional online survey of 8000 Polish adults.

While biological and lifestyle determinants of reproductive health are well documented globally, comprehensive data integrating socio-demographic, lifestyle, and health correlates within a contemporary Polish context remain limited. This study aimed …

Published: Sept. 9, 2026, midnight
Deciphering the Role of ZEB1 as a Central Regulator of Epithelial-Mesenchymal Transition and Hormonal Resistance in Endometriosis.

Endometriosis is a chronic inflammatory and sex steroid hormone-dependent gynaecologic disease, characterised by endometrial cell proliferation outside the uterine cavity, often accompanied by fibrosis, progesterone resistance, and high recurrence despite …

Published: Sept. 9, 2026, midnight
Ectopic Endometrium-Targeted M1 Macrophage-Derived Nanovesicles for Treatment of Endometriosis.

Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies …

Published: Sept. 8, 2026, midnight
Immune regulatory networks and gut microbiota-associated targets in endometriosis: an integrative multi-omics and network analysis.

Endometriosis is an estrogen-dependent disorder characterized by chronic inflammation, immune dysregulation, and altered hormone metabolism. Although gut microbiota-derived metabolites have been implicated in shaping immune microenvironments and lesion development, the …

Published: Sept. 8, 2026, midnight
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.

Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …

Published: Sept. 5, 2026, midnight
Genetic architecture of endometriosis: risk factors, comorbidities and clinical implications.

In 1999, Dr Susan Treloar and colleagues conducted a landmark twin study in Australia and reported their estimate of 51% for the heritability of endometriosis. This important result led several …

Published: Sept. 4, 2026, midnight
Acute appendicitis in a patient with obstructed hemivagina and ipsilateral renal anomaly syndrome: Diagnostic overshadowing in recurrent pelvic pain.

Herlyn-Werner-Wunderlich syndrome, also known as obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome, is a rare congenital Müllerian duct anomaly, occurring in approximately 1 in 1,000,000 females. It is characterised …

Published: Sept. 3, 2026, midnight
Developing biopsychosocial competence in musculoskeletal pain care: Australian physiotherapy educators' perspectives.

A biopsychosocial approach serves as an important paradigm underpinning musculoskeletal pain education training. Understanding how educators teach this approach in their training may provide insights on how to improve the …

Published: Sept. 2, 2026, midnight
Beyond listening: Social media as support, story, and influence in the endometriosis experience.

Social media has emerged as a valuable source of patient-generated data, offering insights into the lived experiences of individuals with endometriosis. While social listening research provides important perspectives on pain, …

Published: Sept. 1, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!